Hovione
Loures, Portugal
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Hovione
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Loures, Portugal
- Modalities
- Dry Powder Inhalation (DPI), Spray Drying / Particle Engineering, Amorphous Solid Dispersion, Nasal Drug Delivery, Drug Substance API
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Hovione
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesDry Powder Inhalation (DPI), Spray Drying / Particle Engineering, Amorphous Solid Dispersion, Nasal Drug Delivery, Drug Substance API
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (5 modalities)
Recent News 10 articles
Portuguese CDMO Hovione completes factory expansions in US, Ireland - Fierce Pharma
Hovione doubles spray drying capacity with $100m US investment round | News - European Pharmaceutical Review
As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec - Fierce Pharma
Hovione certified as a Top Employer in all of its manufacturing sites - PA Media
Hovione invests $100M to expand East Windsor manufacturing - NJBIZ
Hovione to double capacity and create 20 new positions in its Cork factory - businessplus.ie
CEO Spotlight: Hovione’s Jean-Luc Herbeaux - Contract Pharma
Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships - News-Medical
Hovione Expands Spray Drying Capacities in the USA and Ireland - CHEManager
Hovione and Firstgene Announce Strategic Collaboration - CHEManager
Frequently Asked Questions About Hovione
What is Hovione's CDMO Signal Score?
Hovione has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Hovione for a manufacturing program?
Use the free AI matchmaker to compare Hovione against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
Serán Bioscience
Bend, OR
Small Molecule (Oral Solid Dose), Spray Dried Dispersion (SDD), Hot Melt Extrusion (HME), Nano-milling / Nanoparticulate, Fluid Bed Processing, Particle Engineering, Pulmonary / Inhaled Particulates, Nasal Drug Delivery, Finished Dose (tablets, capsules, OPCs, powder-in-bottle)
Forma Life Sciences
Irvine, CA
Multiparticulate Coating, Fluid Bed Granulation & Coating, Modified Release (Controlled/Delayed), Oral Solid Dose, Spray Dried Dispersion, Amorphous Solid Dispersion, Tablet, Capsule
Vectura (now Molex/Vectura)
Chippenham, United Kingdom
Dry Powder Inhalation (DPI), MDI, Inhalation Formulation Development, Device Engineering, Combination Product Manufacturing